

Nucleophilic Labeling Reactions on Synthera: A Multipurpose Synthesis Platform



Alexander Schmitz & Richard Freifelder

University of Pennsylvania, Department of Radiology

Introduction

In the clinical environment, FDG accounts for the vast majority of clinical PET radio-pharmaceuticals. However, when one considers the research side of PET the pallet of options open to the researcher is much broader than FDG.

Home made synthesis units are quite often used because they can nome made symmess units are quite orien used because tiney can be put together in a flexible manner and on a quick time scale. There are also a number of commercial units now available that claim the ability to manufacture multiple compounds with only modest changes in the kits and chemicals (Bioscan, IBA-Molecular, GE, etc.).

At the University of Pennsylvania we nave rocuse on Synthera from IBA-Molecular. In collaboration with IBA-Molecular we have been using the Synthera synthesis unit for a number of 18F radiotracers with very positive results. This solution was chosen for a number of reasons, small size, ready to synthesize FDG, flexibility for other radiotracers. So far we have produced eight compounds with our unit.

To adapt the manual synthesis method of the aforementioned ¹⁸F-radiotracers to our automated Synthera synthesis unit, we evaluated and implemented each synthesis step into the automated synthesis as accurately as possible. Commercially available IFP Nucleophilic¹⁹⁸ for the Synthera box were used for all compounds and experiments.

Goal was to make a minimum of changes to the existing setup to achieve highest convenience while still providing satisfying yields and results. The method and setup should also allow multiple synthesis runs of different radiotracers per day.

Synthesis methods for new radiotracers are to be developed on Synthera according to the goals listed above and results should comply with USP/FDA guidelines.

Based on test experiments, alterations to the synthesis script and method were made to ensure best results and yields with respect to the desired natiotracer. Due to the set goals changes were limited to the variation of parameters like reaction time, temperature and flow rates and the use of different cartridges and solvents, respectively reagents.

After achieving the best parameters for each compound, the script and method was written and saved to the Synthera control computer, several test runs were made to ensure consistent result. SOPs were written and used to follow USP/FDA guidelines.

Except ¹⁸F-FDG all productions runs were single dose syntheses and yielded 10-50mCi (eos) depending on radiotracer.

The graphical interface shows current state of valves, heater and pressure settings.

Methods and scripts can be saved and loaded. The software tests the system and can give warnings if necessary.

We always used IFPTM Nucleophilic synthesis kits. They are individually packed and sealed. The kit is disposable and should only be used once. It is recommended to check the IFP for before use.





18F-F-A853807



The resulting 18F-FA85380 will be for human use and



sis of FDG with Synthera proved to be cons and with yields of 80-85% d.c. on average

The synthesis is compliant with USP and cGMP standards and the resulting FDG was used for human clinical scans at the Hospital of UPenn.



The resulting ¹⁸F-FLT was used for human clinical scans at the Hospital of UPenn and for animal scans.

¹⁸F-Fluoromisonidazole (FMiso)⁵



The $^{18}\mbox{F-FMiso}$ production method was immediately developed on Synthera as a one-pot two-step synthesis. Yields were at 31% (d.c.) on average.

The resulting 18F-FMiso was used for cell studies and animal

The ¹⁸F-Bromofluoroethane production method was immediately developed on Synthera as a one-pot synthesis. Yields were at 23% (d.c.) on average. The single-step one-pot synthesis required a minor change of the IFPTM, an additional valve/cartridge was added.

The resulting ¹⁸F-BFE was then transferred to another synthesis setup for ¹⁸F-Fluroethyl-Labeling.

18F-Fallypride4



Synthesis of ¹⁸F-Fallypride on Synthera showed improvement to the previously used manual setup. Yields for this one-step one-pot reaction were at 36% (d.c.) on average.

The resulting ¹⁸F-Fallypride was used for cell studies

¹⁸F-FHBG²

Synthesis of a random synthesis must be house method adapted from the previously used manual setup. The one-pot two –step synthesis yielded 9% (d.c.) on average and improved significantly.

The resulting 18F-FHBG was used for animal scans and cell

¹⁸F-FP-DTBZ³

Synthesis of ¹⁸F-FP-DTBZ with Synthera showed no improvement to previously used manual setup. This single-step one-pot reaction yielded 6% (d.c.) on average. However, the precursor used was not certified and up to the usual standard.

The resulting ¹⁸F-FP-DTBZ was used for cell studies

Yields and Improvements

	FDG	FLT	FHBG	FP- DTBZ	Fally- pride	BFE	FMiso	F- A85380
Production runs	50	62	8	2	10	7	6	5
Average yield at EOS [%dc]	75	13.6	9	6	36.2	23.7	31.4	34.3
Improvement to previous method	similar	Yield doubled	Yield doubled	similar	Yield 60% increased	*	*	*
Failed runs	1	1	0	0	0	0	0	0

Discussion and Conclusions

Besides FDG routine production, four ¹⁸F-radiotracers (FLT, FHBG, Fallypride and FP-DTBZ) were synthesized at UPenn by a manual synthesis set-up. The Synthera synthesis unit offers a convenient and flexible way to synthesize these compounds under remote conditions. BFE was successfully synthesized with Synthera as an intermediate for fluoroethylation. Synthesis of FMiso and F-A85380 were directly developed on Synthera with great success. Yields were high and consistent and the Synthera unit performed very reliably.

Huge advantages of the Synthera syntheses in comparison to the previously done manual syntheses are less exposure, shorter synthesis duration and improved yledis. Our focus was on the use of the commercially available ITPM Nucleophilic and straight forward adaptation and development of radiotracer syntheses to this setup. Synthera showed great flexibility even with a preset synthesis kit. Changes to script and method are quickly and easily done.

Another advantage of the Synthera unit is to be able to switch between compounds within hours. For a center with both an active clinical and research program this kind of flexibility is crucial. For the FDA, the Synthera unit fulfills necessary regulatory requirements and can be used for human use radiotracer.

- KETEPENCES

 S.J. Oh, C. Moodstanowski, D.Y. Chi, J.Y. Kim, S.H. Kanp, J.S. Ryu, J.S. Yeo, D.H. Moon, Nuclear Medicine and Biology 31 (2004), 803-805.

 G.G. Shue, C.Y.Shue, R.L. Lee, D. MacDonald, R. Hustern, S.L. Eck, A.A. Alaw, Nuclear Medicine and Biology 32 (2001), 802-803.

 Nucl. Med. And Biol. 33 (2006), 6830., wh.E.M.Boom, H.F.Murg, Nucl. Med. And Biol. 33 (2006), 678-803.

 Nucl. Med. And Biol. 34 (

Acknowledgments